SAR studies based on the Stafib-1 compound and rational design led to the development of Stafib-2 with improved and high selective activity against STAT5B in CML cells [324]. The gene discussed is STAT5B; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.